At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has entered into a ...

New York, USA, July 10, 2025 (GLOBE NEWSWIRE) -- Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight ...

Canakinumab shows superior efficacy and safety over anakinra in male patients with VEXAS syndrome, a multicenter study finds.

Interleukin-12 (IL-12) is a heterodimeric pro-inflammatory cytokine that regulates T-cell and natural killer-cell responses, induces the production of interferon-γ (IFN-γ), favours the differentiation ...

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on ...

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival Eleven ...

Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by T cells and macrophages to activate immune responses during infection or after trauma. IL-6 plays an important role in a number of bodily ...

Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712 Peripheral ...

A pleiotropic cytokine central to the regulation of T-cell responses, interleukin 2 (IL-2), plays an essential role in a huge range of other immune modulatory actions. Image Credit: Sino Biological ...